CALGARY, Dec. 10 /CNW/ - Epicore BioNetworks Inc. is pleased to announce
the appointment of a new Aquaculture Business Development Director, Fernando
Garcia Abad. The appointment represents an expansion of Fernando's role, from
responsibility for business development in Latin America to worldwide
responsibility. It supports Epicore's widening involvement in the worldwide
Fernando has over 17 years experience in aquaculture in both academic and
production areas of the business. He graduated with a degree in aquaculture
engineering from the prestigious Universidad Politecnica del Litoral in
Ecuador. He has consulted to the industry and has held management positions in
production facilities at the three key levels of the shrimp industry:
maturations, hatcheries and farms.
Fernando has worked with Epicore for 12 years. For the last eight years
he has been involved with technical support and business development in Latin
America, where Epicore has run a very successful marketing program that
encompasses the Americas as a whole. It has steadily increased its market
position in the region.
Fernando now brings his extensive experience to our worldwide operation.
The worldwide shrimp industry has moved to focus on culturing P. vannamei in
which Epicore has extensive experience. We believe Fernando's promotion will
be welcomed in Asian markets, and will serve to support and enhance our
customer focused, value added approach to meeting their needs.
Epicore BioNetworks Inc. is a leading producer of environmental
biotechnology and animal nutrition products. It manufactures in the USA and
markets worldwide to a variety of industries helping to reduce environmental
pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office
in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange
(symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.)
This press release contains forward-looking statements that involve
significant risks and uncertainties. The actual results, performance or
achievements of the Company might differ materially from the results,
performance or achievements of the Company expressed or implied by such
forward-looking statements. Such forward-looking statements include, without
limitation, those regarding the development plans of the Company and the
expected timing and results of such development. We can provide no assurance
that such development will proceed as currently anticipated or that the
expected timing or results of such development will be realized. We are
subject to various risks, including the uncertainties of product development,
markets for our products and regulatory review, our need for additional
capital to fund our operations, our reliance on collaborative partners, our
history of losses, and other risks inherent in the biotechnology industry.
For further information:
For further information: Mr. William P. Long, (Chief Executive Officer),
Tel: (609) 267-9118